Take advantage of real dealer pricing and shop special offers on new and used boats. Select your boat to get started. A boat's history affects it's value—check the history of this 2005 Crestliner Inc ...

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.

Moderna Inc (MRNA) navigates a challenging quarter with significant cost reductions and strategic partnerships, despite a decline in COVID vaccine demand.

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...

Fortress Biotech (NASDAQ:FBIO)'s Chairman and CEO, Dr. Lindsay (NYSE:LNN) A. Rosenwald, expressed optimism about the vaccine's role in preventing and treating CMV in the future. While analysts ...

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the ...

Nachrichten»Fortress Biotech, Inc.: Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell ...